Literature DB >> 19705503

Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions.

Chun-Li Da1, Yan Xin, Jing Zhao, Xiang-Dong Luo.   

Abstract

AIM: To analyze the differences and relevance of Yes-associated protein (YAP) and survivin, and to explore the correlation and significance of their expression in gastric carcinoma and precancerous lesions.
METHODS: The PV9000 immunohistochemical method was used to detect the expression of YAP and survivin in 98 cases of normal gastric mucosa, 58 intestinal metaplasia (IM), 32 dysplasia and 98 gastric carcinoma.
RESULTS: The positive rates of YAP in dysplasia (37.5%) and gastric carcinoma (48.0%) were significantly higher than that in normal gastric mucosa (13.3%), P < 0.01. The positive rates of survivin in IM (53.4%), dysplasia (59.4%) and gastric carcinoma (65.3%) were significantly higher than in normal gastric mucosa (11.2%), P < 0.01. Survivin expression gradually increased from 41.7% in well differentiated adenocarcinoma through 58.3% in moderately differentiated adenocarcinoma to 75.6% in poorly differentiated adenocarcinoma, with significant Rank correlation, r(k) = 0.279, P < 0.01. The positive rate of survivin in gastric carcinoma of diffused type (74.6%) was significantly higher than that in intestinal type (51.3%), P < 0.05. In gastric carcinoma with lymph node metastasis (76.9%), the positive rate of survivin was significantly higher than that in the group without lymph node metastasis (41.2%), P < 0.01. In 98 cases of gastric carcinoma, the expression of YAP and of survivin were positively correlated, r(k) = 0.246, P < 0.01.
CONCLUSION: YAP may play an important role as a carcinogenic factor and may induce survivin expression. Detecting both markers together may help in early diagnosis of gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19705503      PMCID: PMC2731958          DOI: 10.3748/wjg.15.4055

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Analysis of human transcriptomes.

Authors:  V E Velculescu; S L Madden; L Zhang; A E Lash; J Yu; C Rago; A Lal; C J Wang; G A Beaudry; K M Ciriello; B P Cook; M R Dufault; A T Ferguson; Y Gao; T C He; H Hermeking; S K Hiraldo; P M Hwang; M A Lopez; H F Luderer; B Mathews; J M Petroziello; K Polyak; L Zawel; K W Kinzler
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

2.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma.

Authors:  G Ambrosini; C Adida; D C Altieri
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

3.  Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B.

Authors:  A Tarnawski; R Pai; S-K Chiou; J Chai; E C Chu
Journal:  Biochem Biophys Res Commun       Date:  2005-08-19       Impact factor: 3.575

4.  Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product.

Authors:  M Sudol
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

5.  Control of cell proliferation and apoptosis by mob as tumor suppressor, mats.

Authors:  Zhi-Chun Lai; Xiaomu Wei; Takeshi Shimizu; Edward Ramos; Margaret Rohrbaugh; Nikolas Nikolaidis; Li-Lun Ho; Ying Li
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

6.  Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma.

Authors:  Rainer Lehner; Takayuki Enomoto; James A McGregor; Laurie Shroyer; Bryan R Haugen; Umarani Pugazhenthi; Kenneth R Shroyer
Journal:  Acta Obstet Gynecol Scand       Date:  2002-02       Impact factor: 3.636

7.  Solution structure of human survivin and its binding interface with Smac/Diablo.

Authors:  Chaohong Sun; David Nettesheim; Zhihong Liu; Edward T Olejniczak
Journal:  Biochemistry       Date:  2005-01-11       Impact factor: 3.162

8.  Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.

Authors:  Min Zhang; Neelanjan Mukherjee; R Scott Bermudez; Douglas E Latham; Meaghan A Delaney; Anthony L Zietman; William U Shipley; Arnab Chakravarti
Journal:  Prostate       Date:  2005-08-01       Impact factor: 4.104

9.  Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis.

Authors:  Subham Basu; Nicholas F Totty; Meredith S Irwin; Marius Sudol; Julian Downward
Journal:  Mol Cell       Date:  2003-01       Impact factor: 17.970

10.  yap is required for the development of brain, eyes, and neural crest in zebrafish.

Authors:  Qiu Jiang; Dong Liu; Yuebo Gong; Yuexiang Wang; Shuna Sun; Yonghao Gui; Houyan Song
Journal:  Biochem Biophys Res Commun       Date:  2009-04-22       Impact factor: 3.575

View more
  35 in total

1.  Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis.

Authors:  Andreas Krieg; Billur Baseras; Monika Tomczak; Pablo Emilio Verde; Nikolas Hendrik Stoecklein; Wolfram Trudo Knoefel
Journal:  Mol Biol Rep       Date:  2013-08-15       Impact factor: 2.316

2.  Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes.

Authors:  Jacqueline Brown; Hannelie Bothma; Robin Veale; Pascale Willem
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

3.  A potential role for the Hippo pathway protein, YAP, in controlling proliferation, cell cycle progression, and autophagy in BCPAP and KI thyroid papillary carcinoma cells.

Authors:  Zeming Liu; Wen Zeng; Shi Wang; Xiangwang Zhao; Yawen Guo; Pan Yu; Xingjie Yin; Chunping Liu; Tao Huang
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 4.  Hippo-YAP signaling in digestive system tumors.

Authors:  Feng Yin; Jixin Dong; Liang-I Kang; Xiuli Liu
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

5.  TFF3 and survivin expressions associate with a lower survival rate in gastric cancer.

Authors:  Jia-Rong Meng; Hui-Zhong Tang; Kai-Zong Zhou; Wu-Hong Shen; He-Yi Guo
Journal:  Clin Exp Med       Date:  2012-09-21       Impact factor: 3.984

6.  Inhibitory effects of dobutamine on human gastric adenocarcinoma.

Authors:  Hui-Xia Zheng; Li-Na Wu; Hong Xiao; Qian Du; Jian-Fang Liang
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer.

Authors:  Keun-Wook Lee; Sung Sook Lee; Jun-Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Sang Cheul Oh; Sang Ho Lee; Bo Hwa Sohn; Sang Bae Kim; Jae-Jun Shim; Woojin Jeong; Minse Cha; Jae-Ho Cheong; Jae Yong Cho; Jae Yun Lim; Eun Sung Park; Sang Cheol Kim; Yoon-Koo Kang; Sung Hoon Noh; Jaffer A Ajani; Ju-Seog Lee
Journal:  Clin Cancer Res       Date:  2016-09-21       Impact factor: 12.531

8.  Cytokinesis involves a nontranscriptional function of the Hippo pathway effector YAP.

Authors:  Duyen Amy Bui; Wendy Lee; Anne E White; J Wade Harper; Ron C J Schackmann; Michael Overholtzer; Laura M Selfors; Joan S Brugge
Journal:  Sci Signal       Date:  2016-03-01       Impact factor: 8.192

Review 9.  Monitoring survivin expression in cancer: implications for prognosis and therapy.

Authors:  Rodrigo Santa Cruz Guindalini; Maria Cecília Mathias Machado; Bernardo Garicochea
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

Review 10.  Emerging role of Hippo pathway in gastric and other gastrointestinal cancers.

Authors:  Wei Kang; Alfred S L Cheng; Jun Yu; Ka Fai To
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.